Kura Oncology Files Q1 2025 10-Q
Ticker: KURA · Form: 10-Q · Filed: May 1, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, operations
TL;DR
Kura Oncology's Q1 2025 10-Q is in. Check the Boston Lease and Kyowa Agreement details.
AI Summary
Kura Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations, including details related to its Boston Lease and the Kyowa Agreement. The filing also references its Chief Executive Officer and President, and its common stock.
Why It Matters
This filing provides investors with an update on Kura Oncology's financial health and operational progress for the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Kura Oncology faces inherent risks related to drug development, clinical trials, and regulatory approvals, which are not fully detailed in this summary but are typical for the industry.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter being reported.)
Key Players & Entities
- Kura Oncology, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- Boston Lease (event) — Mentioned in filing
- Kyowa Agreement (event) — Mentioned in filing
- Chief Executive Officer (person) — Mentioned in filing
- President (person) — Mentioned in filing
FAQ
What is the status of the Boston Lease as of March 31, 2025?
The filing indicates that the Boston Lease was active during the period from January 1, 2025, to March 31, 2025.
What is the significance of the Kyowa Agreement mentioned in the filing?
The Kyowa Agreement is referenced in the filing, suggesting it is a material aspect of Kura Oncology's business operations or collaborations.
What financial period does this 10-Q filing cover?
This 10-Q filing covers the first quarter of 2025, ending on March 31, 2025.
Are there any specific drug candidates or research programs highlighted in this filing?
The filing mentions 'Tipifarnib' in the context of operating segments for the period of January 1, 2025, to March 31, 2025, suggesting it is a key area of focus.
What is the company's fiscal year end?
Kura Oncology's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 by Chief Executive Officer regarding Kura Oncology, Inc. (KURA).